To provide direct funding to support the brightest minds in translational research for underfunded cancers at leading cancer centers.
Kure It Inc directs its funding toward translational research for underfunded cancers, with cancer-center grants recurring across multiple years and several awards tied to kidney cancer. Recent grants show a strong concentration of support for major California research institutions, including City of Hope in Duarte and UCI Foundation in Irvine, alongside targeted funding for university-affiliated cancer programs in Los Angeles. The pattern is project-based rather than general institutional support: awards are described as funding cancer research or kidney cancer research, and the foundation’s programs emphasize immediate resources for promising teams and early-stage projects aimed at clinical impact. The grant list also shows that Kure It Inc does not limit itself to one disease site. Its focus areas include appendiceal cancer, cholangiocarcinoma, bladder cancer, chondrosarcoma, colorectal cancer, Ewing sarcoma, gallbladder cancer, liver cancer, lung cancer, liposarcoma, pancreatic cancer, pediatric neuroblastoma, prostate cancer, spine cancer, and stomach cancer, along with genetic sequencing and immunotherapy-related work in some settings. That breadth sits within a consistent framework: direct funding for translational cancer research at leading cancer centers and research institutes.
Kure It Inc repeatedly backs kidney cancer research. One example is a 2023 grant of $150,000 to Keck School of Medicine in Los Angeles for kidney cancer research, and the foundation’s named Rivals United for a Kure grant program is also dedicated to new clinical and translational kidney cancer projects. The foundation also supports broader translational cancer work at major cancer centers. It gave $454,500 to City of Hope in Duarte in 2025 and $267,029 to UCI Foundation in Irvine in 2025, both described as funding cancer research. Other awards point to institutional research settings as the main channel for support, including Cedars-Sinai Medical Center in Beverly Hills and Uc San Diego Foundation in La Jolla. A separate program, Kure It Cares Initiative, targets cancer screening disparities and related community-focused research, including work at the Chao Family Comprehensive Cancer Center. That shows the funder’s portfolio includes both lab-to-clinic research and health equity-oriented projects.
$1M
$974K
$1.3M
$1.5M
Most grants fall between $100K and $175K, with a median of $104K.
25th Percentile
$100K
Median
$104K
75th Percentile
$175K
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Typical awards are large for a targeted research funder: p25 is $100,000, median is $103,750, and p75 is $175,000. The grant list also includes repeated $100,000 awards and larger project grants up to $454,500. Funding appears to recur across years for the same institutions, including City of Hope, UCI Foundation, USC Norris Comprehensive Cancer Center, and Jonsson Cancer Center Foundation. The organization is a nonprofit funder rather than an individual donor, and it does not fund individuals or make program-related investments. Some opportunities are unsolicited, including certain comprehensive-cancer-center grant programs, while others are invitation-limited or named calls.
Kure It Inc gives almost entirely in California: 92% of grants go to recipients in the HQ state, and California is also the top state by grant count. The recent grant list clusters in Duarte, Irvine, Los Angeles, La Jolla, Beverly Hills, and Fullerton. Outside California, one recent award went to Univ Hosp Cleveland Med Ctr in Cleveland, Ohio. The recipient country distribution is entirely domestic, with all recent grants going to U.S. organizations.
Kure It Inc focuses on translational research for underfunded cancers. Its listed focus areas include kidney, appendiceal, bladder, cholangiocarcinoma, chondrosarcoma, colorectal, Ewing sarcoma, gallbladder, liver, lung, liposarcoma, pancreatic, pediatric neuroblastoma, prostate, spine, stomach, and some genetic sequencing and immunotherapy-related work.
Typical grants are six figures. The distribution provided is p25 at $100,000, median at $103,750, and p75 at $175,000. The recent-grant list also includes awards from $50,000 up to $454,500.
Yes. The recent grants show repeat awards to City of Hope, UCI Foundation, USC Norris Comprehensive Cancer Center, and Jonsson Cancer Center Foundation across multiple years, which points to recurring relationships rather than one-time support only.
Some programs accept unsolicited applications. The comprehensive cancer center grant program is marked as accepting unsolicited applications, and Kure It also lists grant request mailing list and RFP/application entry points. Other named opportunities, such as the 2025 Rivals United for a Kure call, are limited to specific centers.
California is the main geography for its giving: 92% of grants go to recipients in the HQ state, and the top state by grant count is also California. Recent recipients include organizations in Duarte, Irvine, Los Angeles, La Jolla, Beverly Hills, and Fullerton.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Current and upcoming funding from Kure It that your nonprofit may be able to apply for.
Who can apply: Applicants must provide complete mailing information. The form requests a supply type, quantity, and comments; the content does not specify additional eligibility requirements.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| CITY OF HOPE | DUARTE, CA | $454,500 | 2025 | TO FUND CANCER RESEARCH |
| UCI FOUNDATION | IRVINE, CA | $267,029 | 2025 | TO FUND CANCER RESEARCH |
| JONSSON CANCER CTR FOUNDATION | LOS ANGELES, CA | $100,000 | 2025 | TO FUND CANCER RESEARCH |
| USC NORRIS COMP CANCER CENTER | LOS ANGELES, CA | $100,000 | 2025 | TO FUND CANCER RESEARCH |
| CEDARS-SINAI MEDICAL CENTER | BEVERLY HILLS, CA | $100,000 | 2025 | TO FUND CANCER RESEARCH |
| CITY OF HOPE | DUARTE, CA | $329,500 | 2024 | TO FUND CANCER RESEARCH |
| UNIV HOSP CLEVELAND MED CTR | CLEVELAND, OH | $250,000 | 2024 | TO FUND CANCER RESEARCH |
| UC SAN DIEGO FOUNDATION | LA JOLLA, CA | $125,000 | 2024 | TO FUND CANCER RESEARCH |
| USC NORRIS COMP CANCER CENTER | LOS ANGELES, CA | $100,000 | 2024 | TO FUND CANCER RESEARCH |
| JONSSON CANCER CTR FOUNDATION | LOS ANGELES, CA | $100,000 | 2024 | TO FUND CANCER RESEARCH |
| SO CAL GENITOURINARY CRC | FULLERTON, CA | $92,500 | 2024 | TO FUND CANCER RESEARCH |
| UCI FOUNDATION | IRVINE, CA | $250,000 | 2023 | TO FUND CANCER RESEARCH |
| KECK SCHOOL OF MEDICINE | LOS ANGELES, CA | $150,000 | 2023 | TO FUND KIDNEY CANCER RESEARCH |
| SO CAL GENITOURINARY CRC | FULLERTON, CA | $107,500 | 2023 | TO FUND CANCER RESEARCH |
| JONSSON CANCER CTR FOUNDATION | LOS ANGELES, CA | $100,000 | 2023 | TO FUND CANCER RESEARCH |
| USC NORRIS COMP CANCER CENTER | LOS ANGELES, CA | $100,000 | 2023 | TO FUND CANCER RESEARCH |
| CITY OF HOPE | DUARTE, CA | $50,000 | 2023 | TO FUND CANCER RESEARCH |
UNIV HOSP CLEVELAND MED CTR
$250,000TO FUND CANCER RESEARCH
SO CAL GENITOURINARY CRC
$92,500TO FUND CANCER RESEARCH
SO CAL GENITOURINARY CRC
$107,500TO FUND CANCER RESEARCH
CITY OF HOPE
$50,000TO FUND CANCER RESEARCH
